Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the industry, enabling a faster and more cost-effective way of discovering new therapies.
Maria Zimina, Business Development Manager of SOM Biotech highlights: “The current pandemic situation has shown that accelerating drug discovery is crucial to address worldwide health emergencies. Repositioning drugs contributes to drastically reduce investment costs and development times. At SOM Biotech, we have successfully applied our AI-based drug discovery platform to look for drug targets and therapies for various conditions obtaining outstanding results. Our recent success in the identification and validation of three drug candidates to treat COVID-19 in a record time of just 4 months, shows that we can respond quickly to acute drug discovery challenges. In this particular case, the high predictivity of our technology allowed us to choose an outstanding candidate out of the three drugs selected, which swiftly obtained positive FDA Pre-IND feedback. This clearly proves that AI-driven drug discovery remains a powerful approach to speed up drug development and change the drug repurposing strategies of the industry for the better.”